Key facts
- Colossal Biosciences’s last known valuation is $10.3B (Sep 2025).
- It has raised $557.6M across 1 recorded rounds; the latest was Later Stage VC ($162.6M) in Jan 2023.
- Notable investors include Climate Capital, Gaingels, Liquid 2 Ventures, Capital Factory, Calm Ventures — 51 tracked in total.
- Colossal Biosciences has filed 2 Form Ds with the SEC since 2023, most recently Jul 2024 ($162.6M sold to 27 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 51 names
- ·Watchlist + deal alerts for Colossal Biosciences
Funding rounds
1 roundsAbout Colossal Biosciences
Operator of a bioscience and genetic engineering company developing technologies to advance genomics. The company applies gene-editing and CRISPR technologies to projects such as extinct species restoration, protection of critically endangered species, and the restoration of ecosystems, enabling environmental organizations to support biodiversity and ecosystem health.
- Sector
- Healthcare
- HQ
- Austin, TX, United States
- Founded
- 2021
- Employees
- 193
- Website
- colossal.com/
- Ownership
- Privately Held (backing)
Colossal Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Colossal Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Colossal Biosciences in its N-PORT filings yet. We sweep new filings monthly.